-Reuters
EF Hutton Initiates Coverage On Fate Therapeutics with Buy Rating, Announces Price Target of $16
EF Hutton analyst Tony Butler initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and announces Price Target of $16.